Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GCK | P35557 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 4/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343683 | 0.94 | MAPT (0.34) | MAPTSMN1; SMN2GCKKMT2AMEN1 | |
| SCHEMBL1341249 | 0.93 | GCK (0.33) | MAPTSMN1; SMN2GCKKMT2AMEN1 | |
| SCHEMBL1341018 | 0.86 | GCK (0.41) | MAPTSMN1; SMN2GCKKMT2AMEN1 | |
| SCHEMBL1342879 | 0.86 | NPC1 (0.36) | MAPTGCKKMT2AMEN1TP53 | |
| SCHEMBL1342577 | 0.85 | TSHR (0.36) | MAPTSMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL1342834 | 0.83 | TSHR (0.38) | MAPTSMN1; SMN2KMT2AMEN1TP53 | |
| SCHEMBL1342966 | 0.82 | CSNK1D (0.35) | MAPTGCKKMT2AMEN1TP53 | |
| SCHEMBL1343073 | 0.82 | GCK (0.39) | MAPTSMN1; SMN2GCKKMT2AMEN1 | |
| SCHEMBL1342682 | 0.81 | GCK (0.45) | MAPTSMN1; SMN2GCKKMT2AMEN1 | |
| SCHEMBL1343678 | 0.80 | MAPT (0.35) | MAPTSMN1; SMN2GCKKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MAPT 2678/4885SMN1; SMN2 2958/4885GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.